During the 2009 H1N1 influenza pandemic, many previously healthy children became critically ill, developing severe pneumonia and respiratory failure, sometimes fatal.
The largest nationwide investigation to date of influenza in critically ill children, led by Children's Hospital Boston, found one key risk factor: Simultaneous infection with methicillin-resistant Staphylococcus aureus (MRSA) increased the risk for flu-related mortality 8-fold among previously healthy children.
Moreover, almost all of these co-infected children were rapidly treated with vancomycin, considered to be appropriate treatment for MRSA. The fact that they died despite this treatment is especially alarming given the rising rates of MRSA carriage among children in the community.
"There's more risk for MRSA to become invasive in the presence of flu or other viruses," says study leader Adrienne Randolph, MD, MsC, of the Division of Critical Care Medicine at Children's Hospital Boston. "These deaths in co-infected children are a warning sign."
The researchers hope their findings, published Nov. 7 by the journal Pediatrics, (eFirst pages) will promote flu vaccination among all children aged 6 months and older. (No flu vaccine is currently available for children younger than 6 months.)
"The 2009 H1N1 virus has not changed significantly to date," notes Tim Uyeki, MD, MPH, of the Influenza Division of the National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), a senior investigator on the study. "Infections of children in the U.S. with 2009 H1N1 virus are expected this season and need to be prevented and treated appropriately. Influenza vaccination protects against 2009 H1N1 illness."
With emergency funding from the National Institutes of Health, Randolph and her colleagues in the Pediatric Acute Lung Injury and Sepsis Investigator's Network tracked 838 children admitted to 35 pediatric ICUs around the country with probable 2009 H1N1 influenza from April 2009 to April 2010. Their vaccination status wasn't consistently known, but H1N1 vaccine did not become available until September 2009 or later.
The median age of the children critically ill with H1N1 was 6 years. Most had respiratory failure, two thirds required mechanical ventilation, and some required extracorporeal membrane oxygenation (ECMO) for advanced cardiac and respiratory support. Their disease progressed rapidly, and 75 children (9 percent) died, two thirds of them within two weeks of ICU admission.
"Some children were quickly overwhelmed, and many died despite centers doing everything to save them," says Randolph. "Early in the pandemic, centers were worried that they would run out of ventilators, that they would run out of ICU beds."
While most of the children critically ill with H1N1 had one or more chronic health conditions that increased their risk, such as asthma, neurologic disorders or compromised immune systems, 251 children (30 percent) were previously healthy.Among these otherwise healthy children, the only risk factor that was identified for death from influenza was a presumed diagnosis of MRSA co-infection in the lung – which increased the risk for mortality 8-fold (P
"It is not common in the U.S. to lose a previously healthy child to pneumonia," says Randolph. "Unfortunately, these children had necrotizing pneumonia – eating away at their tissue and killing off whole areas of the lung. They looked like immunocompromised patients in the way MRSA went through their body. It's not that flu alone can't kill – it can – but in most cases children with flu alone survived."
Use of antiviral agents for critically ill patients with influenza is now routinely recommended. In this study, 88 percent of the children admitted to the ICU received Tamiflu (oseltamivir) during their stay, but only 6 percent had received it prior to hospital admission. Randolph believes it's possible that earlier antiviral treatment might have saved some of these children, especially those who died of influenza without bacterial co-infection. (Influenza antiviral medications work best when given within the first two days of symptom onset.)
The study also found that most of the MRSA co-infected children who died had received vancomycin promptly at or before ICU admission. The researchers aren't sure why this antibiotic of choice didn't save these children – perhaps it couldn't penetrate the lung, or perhaps the disease moved too rapidly.
Physicians seeing children with serious lower-respiratory-tract disease during flu season are urged to give early antiviral treatment (Tamiflu or zanamivir [Relenza]) and antibiotics covering MRSA and other flu-associated bacteria, even before suspected infections are confirmed in the lab, the researchers say.
But other approaches are urgently needed. "MRSA is hard to develop a vaccine against – researchers have been trying since the 1960s and have been unsuccessful," says Randolph. "So the only way to prevent these severe complications is to get everyone vaccinated against the flu, and do more studies of MRSA colonization so we can prevent it in the community and in kids."
A growing threat
Recent studies point to a rise in the number of children carrying MRSA. A study in Pediatrics in 2010 found that the number of children hospitalized for MRSA infection increased from 2 in 1,000 admissions in 1999 to 21 in 1,000 admissions in 2008. This rise was attributed mostly to community-acquired cases – not cases acquired in the hospital.
Many observers attribute the rise to increased use of antibiotics in both people and animals. "The more antibiotics we take, the more we colonize ourselves with antibiotic-resistant organisms such as MRSA," says Randolph.
Influenza appears to suppress the immune response, making children who are already colonized more susceptible to invasive bacterial disease. "Previously, MRSA has not been considered a common cause of pneumonia in kids but this may be changing," Randolph says. "It's likely that flu and other viral infections let MRSA invade and that there's some synergistic reaction between flu and these bacteria."
While recent data show an increase in MRSA co-infection in children dying from seasonal influenza, this is the first study to collect data on a large number of children with no risk factors for severe flu.
The study was funded by the National Institutes of Health, the National Heart Lung and Blood Institute and the Department of Health and Human Services.
Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including nine members of the National Academy of Sciences, 11 members of the Institute of Medicine and nine members of the Howard Hughes Medical Institute comprise Children's research community. Founded as a 20-bed hospital for children, Children's Hospital Boston today is a 395 bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about research and clinical innovation at Children's, visit: http://vectorblog.org.
WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf
First form of therapy for childhood dementia CLN2 developed
25.04.2018 | Universitätsklinikum Hamburg-Eppendorf
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences